This article is more than 5 years old. Information may no longer be current.

FDA approves Rocklatan for open-angle glaucoma, ocular hypertension

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved Rocklatan, a once-daily IOP-lowering eye drop, for patients with open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.

A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP, the release said.

FDA approval is based on data from two phase 3 trials in which Rocklatan demonstrated statistically significant IOP reduction compared with its two individual components.

Aerie plans to launch Rocklatan in the United States in the second quarter.